Rocket Lab Investors Need January Neutron Tank Test Success to Move Toward $90, Not Congressional Alignment
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Shares of Rocket Lab (NASDAQ:RKLB | RKLB Price Prediction) trade at $61.53. Political noise is moving the space trade around, and Rocket Lab’s next leg depends on its Neutron rocket clearing qualification testing.
Rocket Lab is a vertically integrated space company. It flies Electron and HASTE, builds spacecraft and components, and is developing the reusable medium-lift Neutron. The sector mood turned after SpaceX (NASDAQ:SPCX) fell below its $135 IPO price after Democrats won the 2026 midterms. Heading into Q1 2027, the consensus holds that SpaceX’s AI and Starlink momentum can outweigh congressional friction, provided it hits its $33B–$37B Q1 revenue guide. That number sets the sector’s tone. For Rocket Lab, the more important result will come from the Neutron Stage 1 tank.
A Record Backlog Rocket Lab Is Repricing Upward
Q3 revenue reached $267.83M, up 72.7% YoY[1], which beat consensus. Backlog hit $3.57 billion, up 52% since Q2[1]. The first 16 Neutron launches are booked[2] at a base price of $70 million per launch. CFO Adam Spice said, “We could actually have booked more launches in Q3 for Neutron than we did, but we chose to go for higher ASP and lower volumes.”[2]
The company also holds $4.45B[1] in cash. Its Iridium Communications (NASDAQ:IRDM) acquisition is fully funded, which adds a constellation with recurring cash flow.
Neutron Slips Again While Losses and Share Count Climb
The first launch of Neutron is now no earlier than 2027[1]. GAAP EPS of $-0.12[1] missed expectations of $-0.0665. Non-GAAP gross margin fell to 38.4% from 41.9%[3]. The ATM program issued 36.8 million shares[2], and Q4 guidance assumes 681M[1] weighted shares.
Valuation leaves little buffer. Price-to-sales is at 46.95 and forward P/E at about 1,111x. Spice also warned, “Nothing is really going to, I’d say, permanently reverse the cash flow negativity until Neutron is really into production.”[2]
January’s Tank Tests Will Move This Stock More Than Washington
The core business is executing. Profit timing still depends on a rocket that has yet to fly. Peter Beck declined to give a launch date: “Really, until that tank is through the gauntlet of all of its testing, I just don’t want to be continually wrong.”[2] Investors should watch for hydrostatic and cryogenic qualification of the rebuilt tank, regulatory approval for Iridium, and whether launch pricing keeps rising.
Analysts See 51% Upside the Chart Has Yet to Deliver
Rocket Lab trades at $61.53 against a consensus target of $93.10. That means 51.3% upside across 22 analysts. Targets are just a single consideration among many.
- Strong Buy: 5
- Buy: 13
- Hold: 4
The stock is down 11.8% year to date, while the S&P 500 is up 10.62%. Over one year, Rocket Lab rose 35.98% versus 12.25% for the index. Shares trade below the $78.28 200-day average, and beta is 3.176.
Neutron’s Tank Testing Decides Rocket Lab’s Next Move
Rocket Lab’s next move at $61.53 hinges on Neutron’s tank.
The upside catalyst is a Stage 1 tank that passes qualification and a firm 2027 launch window. That would bring forward management’s earlier framework of adjusted EBITDA turning positive about six months after a successful Neutron first flight[2]. The downside risk is another tank failure or a delay further into 2027, especially if margins keep contracting.
Volatility runs high. Shares gained 15.94% in a single week. The downside range is also wide, given a $37.57 52-week low. For Q4, check revenue against the $270M–$290M[1] guide and non-GAAP margin against 39–41%. In Q1 2027, track tank results, the Iridium closing, and SpaceX’s guide as a read on sector sentiment.
A record backlog provides support, but Neutron’s tank determines whether Rocket Lab earns its premium.
Contact [email protected] for any questions or corrections.






